GlaxoSmithKline (GSK) is expected to have two of the top-five best-selling drugs in the respiratory market in 2018, maintaining its strong portfolio of products in this market.
The top-selling drug in 2018 is expected to be a combination therapy for asthma, chronic obstructive pulmonary disorders (COPD), emphysema and bronchitis.
Go deeper with GlobalData
This therapy is a combination of Seretide and Advair, which is forecast to reach sales of $3.4bn in 2018, despite its patent expiry in 2010 and a significant fall in sales from 2017.
Mitigating the loss in revenue
Relvar plus Breo Ellipta, a combination therapy for asthma, COPD, chronic bronchitis and emphysema, is forecast to reach sales of $1.9bn in 2018, and, unlike GSK’s other top-selling drugs, it is forecast to register sales growth in the next few years.
Nucala is a monoclonal antibody that is used for the treatment of asthma and COPD and was first approved in 2015.
It is one of the first and most recent antibodies to enter treatment for asthma and COPD and has shown strong signs of developing into a blockbuster therapy due to its ability to treat severe asthma, which is otherwise untreatable and causes a severe reduction in patients’ quality of life.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
